New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imatinib mesilate 477.88mg equivalent to imatinib 400 mg;   - capsule - 400 mg - active: imatinib mesilate 477.88mg equivalent to imatinib 400 mg   excipient: crospovidone gelatin iron oxide black iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.988 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; citric acid; sodium citrate; sodium chloride; nitrogen - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.977 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: sodium chloride; sodium citrate; citric acid; water for injections; nitrogen - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pemetrexed disodium hemipentahydrate 120.82mg equivalent to 100 mg pemetrexed - powder for infusion - 100 mg - active: pemetrexed disodium hemipentahydrate 120.82mg equivalent to 100 mg pemetrexed excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma: pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pemetrexed disodium hemipentahydrate 604.12mg equivalent to 500 mg pemetrexed - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.12mg equivalent to 500 mg pemetrexed excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma: pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - elexacaftor 100mg;  ; ivacaftor 75mg;  ;  ; tezacaftor 50mg;  ;  ; ivacaftor 150mg - film coated tablet - active: elexacaftor 100mg   ivacaftor 75mg     tezacaftor 50mg     excipient: croscarmellose sodium hypromellose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry orange 20a130039 sodium laurilsulfate active: ivacaftor 150mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry blue 85f90614 sodium laurilsulfate - trikafta is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - elexacaftor 50mg;  ; ivacaftor 37.5mg;  ;  ; tezacaftor 25mg;  ;  ; ivacaftor 75mg - film coated tablet - active: elexacaftor 50mg   ivacaftor 37.5mg     tezacaftor 25mg     excipient: croscarmellose sodium hypromellose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry orange 20a130039 sodium laurilsulfate active: ivacaftor 75mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry blue 85f105098 sodium laurilsulfate - trikafta is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 190mg; metoprolol succinate 190mg; metoprolol succinate 190mg - modified release tablet - 190 mg - active: metoprolol succinate 190mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 190mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 190mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 23.75mg; metoprolol succinate 23.75mg; metoprolol succinate 23.75mg - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 47.5mg; metoprolol succinate 47.5mg; metoprolol succinate 47.5mg - modified release tablet - 47.5 mg - active: metoprolol succinate 47.5mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 47.5mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 47.5mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.